首頁 > 市場調查報告書 > 醫療設備

生技設備基因治療學和RNAi

市場調查報告書

商品編碼

2126400

轉錄組生物標記市場－策略分析與預測（2026-2035）

Transcriptomic Biomarkers Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月10日 | 出版商:

Knowledge Sourcing Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

轉錄組生物標記市場預計將從 2026 年的 63.2 億美元成長到 2035 年的 169.2 億美元，複合年成長率為 11.6%。

轉錄組生物標記市場正經歷模式轉移、RNA表達特徵作為生物活性動態指標的日益普及，以及轉錄組分析在藥物研發和臨床實踐中日益廣泛的應用。這個市場演變的特點在於，人們逐漸認知到轉錄組生物標記物能夠捕捉動態的細胞活動，並反映組織和循環體液中持續的生物學變化，而這些變化僅靠基因組分析無法完全捕捉。先進的RNA定序技術、人工智慧和多體學整合的融合，使得更全面、更靈敏、更具臨床應用價值的分子表徵成為可能。由於傳統的診斷方法往往無法捕捉分子異質性，醫療服務提供者正日益尋求能夠區分生物學上相似疾病的生物標記。製藥公司正在將轉錄組生物標記應用於藥物研發的各個環節，因為基於生物標記的臨床試驗能夠改善患者分層，並提高療效驗證的可能性。該市場正在大力投資 RNA定序平台、單細胞轉錄組學和人工智慧驅動的生物標記發現，轉錄組生物標記正在成為精準醫療和個人化醫療的關鍵組成部分。

市場促進因素

精準腫瘤學計畫的拓展是轉錄組生物標記市場的主要驅動力。精準腫瘤學基於分子層面的特徵分析，識別最有可能從標靶治療中獲益的患者。 RNA表現模式揭示了僅靠基因測序無法完全捕捉的活躍生物通路，從而增加了對轉錄組生物標記的需求。當分子層次分層不完整時，生物異質性會限制治療效果。因此，製藥公司正在將轉錄組分析納入伴隨診斷和生物標記主導的臨床試驗的開發中，從而推動了轉錄組生物標記應用的持續成長。隨著生物標記擴大被整合到藥物研發中，對動態動態資訊的需求也在不斷成長，進一步加速了市場成長。藥物研發越來越依賴已驗證的生物標記來識別對治療有反應的患者群體，並在整個臨床試驗過程中檢驗生物活性。轉錄組生物標記提供的動態動態資訊可以補充基因組檢測在治療評估中的作用。在異質性疾病中，當需要在受試者入組前進行分子層級分層時，臨床試驗的複雜性會增加。因此，製藥公司正在增加對RNA定序、多重檢測和轉化生物標記項目的投資。轉錄組分析技術的進步正在提高分析靈敏度、處理能力和定量重複性。轉錄組技術在分析靈敏度、處理能力和定量重複性方面持續改進。 RNA定序因其能夠全面檢測不同生物檢體中的編碼和非編碼RNA分子，正被越來越多的檢查室所採用。傳統的表達分析方法在複雜疾病的分子水平解析度方面往往存在局限性。因此，技術開發人員正致力於改善定序化學、自動化平台、數位PCR系統和生物資訊工作流程。多組體學研究計畫的擴展正在加強生物標記的發現和轉化醫學。生物醫學研究正擴大將基因組、轉錄組、蛋白質組和代謝組資訊結合，以全面了解疾病機制。轉錄組生物標記在將基因組突變與功能性生物活性聯繫起來方面發揮核心作用。

市場限制因素

轉錄組生物標記在常規臨床應用前，需要在不同患者群體中獲得可重複的證據，這導致了廣泛的臨床檢驗要求。這些嚴格的證據要求為開發者帶來了巨大的時間和成本負擔。定序平台、分析流程以及整個生物資訊流程中仍存在標準化方面的挑戰，限制了研究間的可比較性和監管協調。缺乏統一的方案降低了可比性和臨床可靠性。與新一代定序（NGS）、計算分析和專業實驗室技術相關的高昂基礎設施成本，持續限制資源有限的醫療機構的應用。先進技術所需的大量資金投入，對小規模的醫療機構而言也是一大障礙。不同司法管轄區的複雜法規，也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

對技術和生物標記類型的深入了解

技術發展趨勢的特徵是RNA定序、單細胞轉錄組學和人工智慧驅動的分析日益重要。 RNA測序（RNA-Seq）因其高分析靈敏度和能夠無偏地表徵整個轉錄組中的編碼和非編碼RNA分子而成為領先技術。隨著研究機構和製藥公司對能夠識別新型生物標記、剪接變異、融合轉錄物和基因表現差異模式的全面分子譜分析的需求不斷成長，RNA定序的需求也持續上升。傳統的微陣列平台轉錄物覆蓋範圍有限，且缺乏在新生物標記發現應用中的柔軟性。因此，技術供應商正致力於改進定序化學流程、自動化系統、基於雲端的生物資訊學和可擴展的運算工作流程。在某些需要快速獲得結果的基因表現分析中，qPCR仍然扮演著至關重要的角色。片段分析表明，mRNA生物標記佔據了最大的功能片段，因為它們直接反映了與疾病進展、治療反應和細胞分化相關的基因轉錄活性。隨著臨床醫生需要動態分子指標來監測治療過程中的生物學變化，基於mRNA的生物標記的需求日益成長。隨著調控性RNA分子臨床意義的不斷提升，微型RNA和lncRNA生物標記的應用也不斷擴展。腫瘤學是其主要應用領域，因為癌症發展涉及基因表現的持續變化，這些變化會影響腫瘤形成、免疫逃脫、轉移和治療抗藥性。神經病學、心血管疾病、感染疾病和呼吸系統疾病也是重要且快速成長的應用領域。製藥和生物技術公司佔據了主要的終端用戶群體，轉錄組檢測在醫院和臨床診斷檢查室的應用能力也在不斷提升。人工智慧的整合變得日益重要，因為它能夠透過識別與疾病結局相關的複雜分子模式，高效解讀高維轉錄組資料集。

競爭格局與策略展望

在競爭激烈的市場環境中，除了成熟的定序和生命科學公司外，還有專注於轉錄組學、單細胞生物學和空間生物學的供應商加入競爭。 Illumina憑藉其NGS平台、全面的定序試劑和整合的生物資訊解決方案保持主導地位，並持續擴大與製藥公司和研究機構的合作，以加速生物標記的發現、伴隨診斷的開發以及精準醫療的應用。 Thermo Fisher Scientific提供廣泛的RNA定序、qPCR、樣本製備和生物資訊解決方案，以支持轉錄組生物標記的研究和臨床應用，其整合的工作流程策略使製藥公司和臨床檢查室能夠產生標準化的分子數據。 Roche將其在製藥領域的專業知識與Roche Diagnostics的先進分子診斷技術相結合，以加強轉錄組生物標記在個人化醫療中的整合，同時持續投資於伴隨診斷和精準腫瘤學計畫。 QIAGEN提供分子樣本製備技術、RNA分析檢測、生物資訊平台和伴隨診斷解決方案，以加速轉錄組生物標記的工作流程，並透過策略夥伴關係關係擴大其在臨床領域的應用。安捷倫透過基因組學儀器、微陣列平台、自動化實驗室解決方案和分析軟體，為轉錄組生物標記研究提供支援。 Bio-Rad 提供數位 PCR、qPCR、多重檢測系統和生命科學研究產品，可實現高靈敏度的 RNA 生物標記檢測和檢驗。兩家公司都在致力於透過 RNA定序平台、單細胞轉錄組學和人工智慧驅動的發現工具的創新來擴展產品系列。在生物標記發現和檢驗需求的驅動下，定序提供者、製藥公司和研究機構之間的策略夥伴關係日益增多。近期一項重大進展是 Caris 推出了其癌症診斷產品組合中的新產品「Caris Detect」。 10x Genomics 發布了 Atera，這是一個旨在以高通量和單細胞靈敏度測量整個轉錄組生物學特性的新型空間生物學平台。 Illumina 宣布了一項新的太空技術計劃，用於繪製複雜組織圖譜並以前所未有的規模研究細胞行為。地理擴張仍然是兩家公司的關鍵策略重點，它們都將目光投向了快速成長的亞太地區和醫療基礎設施不斷完善的新興市場。

簡明結論

轉錄組生物標記市場預計將持續成長，這主要得益於精準醫療、技術創新以及與製藥業的融合。從探索性研究到常規臨床應用的轉變，標誌著分子診斷領域的根本性變革。儘管臨床檢驗、標準化和基礎設施成本等方面的挑戰仍然存在，但對技術、夥伴關係以及證據產生的策略性投資正為市場領導帶來持續的競爭優勢。隨著轉錄組生物標記逐漸成為精準醫療的關鍵組成部分，在全球醫療保健系統中支持疾病表徵、治療方案開發和患者預後改善，其長期市場前景仍然光明。

本報告的主要益處：

深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
實用建議：我們支援制定策略決策，以開發新的收入來源。
適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
競爭對手定位、策略和市場佔有率分析
營收成長率及預測分析：依業務板塊及地區（國家）分類
企業概況（策略、產品、財務資訊、關鍵趨勢等）

市場定義和範圍
行業概覽
轉錄組生物標記的演變
主要市場趨勢
實際成果值市場規模分析
市場預測
轉錄組生物標記在精準醫療工作流程中的作用
疾病負擔和轉錄組生物標記的臨床需求
疾病盛行率和確診患者人數分析
從生物標記發現到臨床實用化的工作流程
臨床引入趨勢

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

新的轉錄組分析技術
產品創新
臨床試驗分析
管道分析
人工智慧與機器學習的融合
多體學整合與空間轉錄組學
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求

第8章：全球轉錄組生物標記市場：展望分析

分析：按技術平台
分析：依生物標記類型
分析：依檢體類型
分析：透過臨床應用
分析：透過測試方法

第9章全球轉錄組生物標記市場：細分市場分析

依生物標誌類型
- 傳訊RNA（mRNA）生物標記
- 微型RNA（miRNA）生物標記
- 長鏈非編碼RNA（lncRNA）生物標記
透過技術
- RNA定序（RNA-Seq）
- 定量PCR（qPCR）
- 微陣列
- 其他轉錄組學技術
依檢體類型
- 血
- 組織
- 唾液
- 尿
- 其他類型的檢體
透過使用
- 腫瘤學
- 神經病學
- 心血管疾病
- 感染疾病
- 呼吸系統疾病
- 其他用途
最終用戶
- 醫院
- 臨床診斷檢測實驗室
- 學術研究機構
- 製藥和生物技術公司
- 其他最終用戶

第10章：全球轉錄組生物標記市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球轉錄組生物標記市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
瑞士
中國
日本
韓國
印度
澳洲
巴西

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

Illumina, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
QIAGEN NV
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Bruker Corporation
Standard BioTools Inc.
Oxford Nanopore Technologies plc
10x Genomics, Inc.

第14章全球轉錄組生物標記市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009112

The Transcriptomic Biomarkers Market is expected to increase at a CAGR of 11.6% from a market size of USD 6.32 billion in 2026 to USD 16.92 billion in 2035.

The transcriptomic biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision medicine, the growing recognition of RNA expression signatures as dynamic indicators of biological activity, and the increasing integration of transcriptomic profiling into drug development and clinical practice. The market's evolution is characterized by the understanding that transcriptomic biomarkers capture dynamic cellular activity, reflecting ongoing biological changes within tissues and circulating biofluids that genomic analysis alone cannot fully capture. The convergence of advanced RNA sequencing technologies, artificial intelligence, and multi-omics integration is enabling more comprehensive, sensitive, and clinically actionable molecular characterization. Healthcare providers are increasingly requiring biomarkers capable of distinguishing biologically similar diseases because conventional diagnostic approaches often fail to capture molecular heterogeneity. Pharmaceutical companies are incorporating transcriptomic biomarkers throughout drug development because biomarker-guided clinical trials improve patient stratification and enhance the probability of demonstrating therapeutic benefit. The market is witnessing significant investment in RNA sequencing platforms, single-cell transcriptomics, and AI-enabled biomarker discovery, positioning transcriptomic biomarkers as a critical component of precision medicine and personalized healthcare.

Market Drivers

The expansion of precision oncology programs represents the primary driver for the transcriptomic biomarkers market. Precision oncology relies on molecular characterization to identify patients who are most likely to benefit from targeted therapies. Demand is increasing for transcriptomic biomarkers because RNA expression patterns reveal active biological pathways that genomic sequencing alone cannot fully capture. Biological heterogeneity limits treatment effectiveness when molecular stratification remains incomplete. Pharmaceutical companies are therefore incorporating transcriptomic profiling into companion diagnostic development and biomarker-driven clinical trials, resulting in sustained growth in transcriptomic biomarker utilization. The increasing integration of biomarkers into drug development is further accelerating market growth through demand for dynamic pharmacodynamic information. Drug development increasingly depends on validated biomarkers that identify responsive patient populations and monitor biological activity throughout clinical trials. Transcriptomic biomarkers provide dynamic pharmacodynamic information that complements genomic testing during therapeutic evaluation. Clinical trial complexity increases when heterogeneous diseases require molecular stratification before enrollment. Pharmaceutical sponsors are consequently expanding investments in RNA sequencing, multiplex assays, and translational biomarker programs. Technological advancements in transcriptomic analysis are improving analytical sensitivity, throughput, and quantitative reproducibility. Transcriptomic technologies continue improving analytical sensitivity, throughput, and quantitative reproducibility. Laboratories are increasingly adopting RNA sequencing because it enables the comprehensive detection of coding and non-coding RNA molecules across diverse biological samples. Conventional expression analysis often provides limited molecular resolution for complex diseases. Technology developers are therefore enhancing sequencing chemistry, automation platforms, digital PCR systems, and bioinformatics workflows. The expansion of multi-omics research programs is strengthening biomarker discovery and translational medicine. Biomedical research increasingly combines genomic, transcriptomic, proteomic, and metabolomic information to understand disease mechanisms comprehensively. Transcriptomic biomarkers occupy a central role because they connect genomic variation with functional biological activity.

Market Restraints

Clinical validation requirements remain extensive because transcriptomic biomarkers require reproducible evidence across diverse patient populations before routine clinical implementation. The rigorous evidence requirements create significant time and cost burdens for developers. Standardization challenges persist across sequencing platforms, analytical workflows, and bioinformatics pipelines, limiting cross-study comparability and regulatory harmonization. The lack of harmonized protocols reduces comparability and clinical confidence. High infrastructure costs associated with NGS, computational analysis, and specialized laboratory expertise continue restricting adoption among resource-constrained healthcare institutions. The significant financial investment required for advanced technologies creates barriers for smaller facilities. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Biomarker Type Insights

The technology landscape is characterized by the growing importance of RNA sequencing, single-cell transcriptomics, and AI-enabled analytics. RNA-Seq constitutes the leading technology because it enables unbiased, transcriptome-wide characterization of coding and non-coding RNA molecules with high analytical sensitivity. Demand is continuously increasing as research organizations and pharmaceutical companies require comprehensive molecular profiling capable of identifying novel biomarkers, splice variants, fusion transcripts, and differential gene expression patterns. Traditional microarray platforms provide limited transcript coverage and reduced flexibility for emerging biomarker discovery applications. Technology providers are consequently improving sequencing chemistry, automation systems, cloud-based bioinformatics, and scalable computational workflows. qPCR remains important for focused gene expression analysis where rapid turnaround is prioritized. The segment analysis reveals that mRNA biomarkers represent the largest functional segment because they directly reflect gene transcription activity associated with disease progression, therapeutic response, and cellular differentiation. Demand is increasingly shifting toward mRNA-based biomarkers as clinicians require dynamic molecular indicators capable of monitoring biological changes throughout treatment. MicroRNA and lncRNA biomarkers are expanding as regulatory RNA molecules gain clinical relevance. Oncology represents the dominant application because cancer development involves continuous alterations in gene expression that influence tumor initiation, immune evasion, metastasis, and treatment resistance. Neurology, cardiovascular diseases, infectious diseases, and respiratory diseases represent significant and growing application areas. Pharmaceutical and biotechnology companies represent the leading end-user segment, with hospitals and clinical diagnostic laboratories expanding transcriptomic testing capabilities. The integration of AI is becoming increasingly important because AI enables efficient interpretation of high-dimensional transcriptomic datasets by identifying complex molecular patterns associated with disease outcomes.

Competitive and Strategic Outlook

The competitive landscape features established sequencing and life science companies alongside specialized transcriptomics, single-cell, and spatial biology providers. Illumina maintains a leading position through its NGS platforms, comprehensive sequencing reagents, and integrated bioinformatics solutions, continuing to expand collaborations with pharmaceutical and research organizations to accelerate biomarker discovery, companion diagnostic development, and precision medicine applications. Thermo Fisher Scientific offers an extensive portfolio of RNA sequencing, qPCR, sample preparation, and bioinformatics solutions that support transcriptomic biomarker research and clinical translation, with an integrated workflow strategy enabling pharmaceutical companies and clinical laboratories to generate standardized molecular data. Roche combines its pharmaceutical expertise with advanced molecular diagnostics through Roche Diagnostics, strengthening the integration of transcriptomic biomarkers into personalized healthcare, continuing to invest in companion diagnostics and precision oncology programs. QIAGEN provides molecular sample preparation technologies, RNA analysis assays, bioinformatics platforms, and companion diagnostic solutions that facilitate transcriptomic biomarker workflows, with strategic partnerships expanding clinical adoption. Agilent supports transcriptomic biomarker research through genomics instruments, microarray platforms, automated laboratory solutions, and analytical software. Bio-Rad delivers digital PCR, qPCR, multiplex assay systems, and life science research products that enable sensitive RNA biomarker detection and validation. Companies are pursuing product portfolio expansion through innovation in RNA sequencing platforms, single-cell transcriptomics, and AI-enabled discovery tools. Strategic collaborations between sequencing providers, pharmaceutical companies, and research institutions are increasing, driven by the need for biomarker discovery and validation. Recent key developments include Caris launching Caris Detect as a new product offering in its cancer diagnostics portfolio. 10x Genomics introduced Atera, a new spatial biology platform built to measure whole-transcriptome biology at high throughput and single-cell sensitivity. Illumina announced a new spatial technology program to map complex tissues and study cellular behavior at an unprecedented scale. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The transcriptomic biomarkers market is positioned for sustained growth driven by the convergence of precision medicine, technological innovation, and pharmaceutical integration. The transition from exploratory research toward routine clinical implementation represents a fundamental shift in molecular diagnostics. While challenges related to clinical validation, standardization, and infrastructure costs persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with transcriptomic biomarkers evolving into a critical component of precision medicine, supporting disease characterization, therapeutic development, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Transcriptomic Biomarkers Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Evolution of Transcriptomic Biomarkers
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Role of Transcriptomic Biomarkers Across the Precision Medicine Workflow
3.8 Disease Burden and Clinical Need for Transcriptomic Biomarkers
3.9 Disease Prevalence and Diagnosed Patient Population Analysis
3.10 Biomarker Discovery to Clinical Commercialization Workflow
3.11 Clinical Adoption Landscape

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Transcriptomic Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Artificial Intelligence and Machine Learning Integration
6.6 Multi-Omics Integration and Spatial Transcriptomics
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Transcriptomic Biomarkers Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker Type
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology

9. Global Transcriptomic Biomarkers Market Segment Analysis (2021-2035)

9.1 By Biomarker Type
- 9.1.1 Messenger RNA (mRNA) Biomarkers
- 9.1.2 MicroRNA (miRNA) Biomarkers
- 9.1.3 Long Non-Coding RNA (lncRNA) Biomarkers
9.2 By Technology
- 9.2.1 RNA Sequencing (RNA-Seq)
- 9.2.2 Quantitative PCR (qPCR)
- 9.2.3 Microarray
- 9.2.4 Other Transcriptomic Technologies
9.3 By Sample Type
- 9.3.1 Blood
- 9.3.2 Tissue
- 9.3.3 Saliva
- 9.3.5 Urine
- 9.3.6 Other Sample Types
9.4 By Application
- 9.4.1 Oncology
- 9.4.2 Neurology
- 9.4.3 Cardiovascular Diseases
- 9.4.4 Infectious Diseases
- 9.4.5 Respiratory Diseases
- 9.4.6 Other Applications
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Clinical Diagnostic Laboratories
- 9.5.3 Academic & Research Institutes
- 9.5.4 Pharmaceutical & Biotechnology Companies
- 9.5.5 Other End Users

10. Global Transcriptomic Biomarkers Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Transcriptomic Biomarkers Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Netherlands
11.9 Switzerland
11.10 China
11.11 Japan
11.12 South Korea
11.13 India
11.14 Australia
11.15 Brazil

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 Illumina, Inc.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Thermo Fisher Scientific Inc.
13.3 F. Hoffmann-La Roche Ltd.
13.4 QIAGEN N.V.
13.5 Agilent Technologies, Inc.
13.6 Bio-Rad Laboratories, Inc.
13.7 Bruker Corporation
13.8 Standard BioTools Inc.
13.9 Oxford Nanopore Technologies plc
13.10 10x Genomics, Inc.